There are currently 1380 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Healthcare of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Piedmont Heart Institute, Atlanta, Georgia +1 locations
Conditions: Coronary Artery Disease
Register for Updates
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
NCT05238220
Recruiting
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2022
Locations: Piedmont Atlanta Hospital, Atlanta, Georgia
Conditions: Kidney Transplant; Complications
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Lymphangioleiomyomatosis
Register for Updates
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
NCT04598698
Recruiting
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visi... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
01/11/2022
Locations: Academia of Women's Health and Endoscopic Surgery, Atlanta, Georgia
Conditions: Endometriosis
Register for Updates
Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms
NCT04819074
Recruiting
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically app... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2021
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Aneurysm, Brain
Register for Updates
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
NCT05027997
Recruiting
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Blepharospasm, Dystonia
Register for Updates
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
NCT05110963
Recruiting
Retention in care and persistent adherence to antiretroviral therapy are necessary for the successful treatment of HIV infection. HIV-related stigma is a known impediment to the care and health outcomes of people living with HIV. The proposed study will test theory-based interventions designed to manage HIV stigma in order to improve care retention and medication adherence in communities with high-levels of HIV-related stigma.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV I Infection
Register for Updates
HIV Treatment Adherence Dose Determination Trial
NCT04577313
Recruiting
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV Infections
Register for Updates
Dietary Oxysterols and β-Cell Function Among African Americans
NCT05072587
Recruiting
African Americans (AAs) have a higher risk of developing type 2 diabetes than the general population. AAs are also more likely to eat foods that contain cholesterol oxides/oxysterols. Dietary oxysterols can harm the cells that produce insulin and decrease insulin production. This pilot study seeks to determine if removing dietary oxysterols with a plant-based diet will improve insulin production and decrease the risk of type 2 diabetes among AAs.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/08/2021
Locations: Morehouse School of Medicine, Atlanta, Georgia
Conditions: Type 2 Diabetes
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Atlanta Diabetes, Atlanta, Georgia
Conditions: Diabetes
Register for Updates
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
NCT01908192
Recruiting
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/10/2021
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Schizophrenia
Register for Updates
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Recruiting
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Relapsed Refractory Multiple Myeloma
Register for Updates